contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


amniotics-granted-key-us-patent-for-pulmostemtm

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC).

The company is listed at Nasdaq First North Growth Market in Stockholm.

Amniotics

Amniotics (publ) (Nasdaq Stockholm: AMNI) announced today that the US Patent and Trademark Office (USPTO) has approved a patent application for the company’s stem cell product PulmoStem™. This...

<div class="mfn-preamble"><p><strong>Amniotics (publ) (Nasdaq Stockholm: AMNI) announced today that the US Patent and Trademark Office (USPTO) has approved a patent application for the company’s stem cell product PulmoStem™. This newly allowed U.S. patent, with application no. 17/646539, “Use of term amniotic fluid cells for the treatment of acute and chronic respiratory disease”, provides Amniotics with exclusive commercial rights in the U.S. at least until 2040 for the use of the amniotic derived stem cell product PulmoStem™ in the treatment of Acute Respiratory Distress Syndrome (ARDS).</strong></p></div><div class="mfn-body"><p>Amniotics stem cell product PulmoStem™ is expected to be efficacious in various acute and chronic diseases of the lung through modulation of the immune response and anti-fibrotic capabilities. The first clinical study to commence this summer is targeting hospitalized patients suffering from respiratory tract infections due to COVID-19 and other causes, which can cause ARDS.</p><p>“This is the first U.S. patent granted in Amniotics patent portfolio and it confirms that our stem cell products and production methods are patentable, novel, and innovative. This approval also validates our long-term IP strategy, matching high quality patent applications with Amniotics products, ensuring market exclusivity for Amniotics technology. This is a great milestone, reached via a team effort, and I want to take the opportunity to thank our founders, inventors, and external consultants including our corporate patent advisor Dominic Davies and our US IP partner Knobbe Martens”, says Kåre Engkilde, CEO at Amniotics</p></div><div class="mfn-footer mfn-aafd572f474a"><p><strong class="mfn-heading-1">For more information please contact</strong></p><hr><p>Kåre Engkilde<br>CEO, Amniotics AB<br>Phone: +46 (0) 723 27 85 20<br>Email:&nbsp;<a rel="nofollow noopener" href="mailto:ke@amniotics.com">ke@amniotics.com</a><br>or<br>Johny Humaloja<br>CFO, Amniotics AB<br>Phone: +46 (0) 735 0668 56<br>Email: <a rel="nofollow noopener" href="mailto:jh@amniotics.com">jh@amniotics.com</a></p></div><div class="mfn-footer mfn-about mfn-b652d04a8121"><p><strong class="mfn-heading-1">About Amniotics</strong></p><hr><p>Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.</p><p>Amniotics (publ) has it´s headquarter in Lund, Sweden.</p><p>Amniotics Certified Adviser on First North is Redeye AB, <a rel="nofollow noopener" href="mailto:certifiedadviser@redeye.se">certifiedadviser@redeye.se</a>, telephone: +46 (0) 8&nbsp;121&nbsp;576 90.</p><p>The company is listed at Nasdaq First North Growth Market in Stockholm.</p><p>Learn more at&nbsp;<a rel="nofollow noopener" href="http://www.amniotics.com">www.amniotics.com</a>.&nbsp;</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/370ea1e0-53c2-4d38-b122-3697bc04c9f6/amniotics-granted-key-u-s-patent-for-pulmostem.pdf" class="mfn-generated mfn-primary">Amniotics granted key U.S. patent for PulmoStem™</a></p></div>